ATYR
USDaTyr Pharma Inc. Common Stock
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$5.550
Haut
$5.749
Bas
$5.330
Volume
2.00M
Fondamentaux de l'Entreprise
Capitalisation Boursière
480.2M
Industrie
Biotechnologie
Pays
United States
Statistiques de Trading
Volume Moyen
1.63M
Bourse
NCM
Devise
USD
Intervalle sur 52 Semaines
Actualités Connexes
HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma with a Buy and maintains $35 price target.
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world
HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma with a Buy and maintains $35 price target.
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 16, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from
Actions Connexes
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.